Commercial Metals (CMC)
NYSE: CMC
· Real-Time Price · USD
57.05
0.04 (0.07%)
At close: Sep 24, 2025, 3:59 PM
57.49
0.78%
After-hours: Sep 24, 2025, 06:59 PM EDT
0.07% (1D)
| Bid | 56.25 |
| Market Cap | 6.39B |
| Revenue (ttm) | 7.68B |
| Net Income (ttm) | 36.81M |
| EPS (ttm) | 0.3 |
| PE Ratio (ttm) | 190.15 |
| Forward PE | 11.98 |
| Analyst | Hold |
| Dividends | $0.9 |
| Ask | 58 |
| Volume | 491,581 |
| Avg. Volume (20D) | 1,172,524.2 |
| Open | 56.96 |
| Previous Close | 57.01 |
| Day's Range | 56.88 - 57.55 |
| 52-Week Range | 37.92 - 64.53 |
| Beta | 1.33 |
| Ex-Dividend Date | Jun 30, 2025 |
Analyst Forecast
According to 0 analyst ratings, the average rating for CMC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCommercial Metals is scheduled to release its earnings on
Oct 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+0.04%
Shares of steel companies are trading lower follow...
Unlock content with
Pro Subscription
4 months ago
+5.1%
Shares of metals stocks are trading higher amid overall market strength after the US and China agreed to a temporary reduction in most tariffs on each other's goods. A decrease of trade tensions could reduce demand uncertainty for base metals.
2 months ago · seekingalpha.com
Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, BuyingInitiating coverage on Unicycive Therapeutics, Inc. with a Buy rating and $6 price target, as the recent FDA CRL is manufacturing-related and resolvable. OLC's ultra-low pill burden and strong patient...
